German construction sector still in recession, civil engineering only bright spot
SOUTH SAN FRANCISCO - Spruce Biosciences, Inc. (NASDAQ:SPRB) will resume trading on the Nasdaq Capital Market today, September 15, 2025, the company announced in a press release. The stock, which has shown significant volatility with a 37.78% gain in the past week, currently trades at $12.40.
The late-stage biopharmaceutical company, which focuses on developing therapies for neurological disorders, will trade under the ticker symbol SPRB with the CUSIP number 85209E 208. According to InvestingPro analysis, the company maintains a healthy balance sheet with more cash than debt and a current ratio of 2.6.
The company describes itself as focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.
The press release did not specify the reason for the trading resumption or indicate how long the company’s shares had been suspended from trading prior to today’s announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.